These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. The Orphan Drug Act: an engine of innovation? At what cost? Rohde DD Food Drug Law J; 2000; 55(1):125-43. PubMed ID: 12322720 [No Abstract] [Full Text] [Related]
44. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2007; 20(1):45-55. PubMed ID: 17332899 [TBL] [Abstract][Full Text] [Related]
45. Deterring the importation of counterfeit pharmaceutical products. Stearn DW Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351 [No Abstract] [Full Text] [Related]
46. Orphan drug legislation: lessons for neglected tropical diseases. Villa S; Compagni A; Reich MR Int J Health Plann Manage; 2009; 24(1):27-42. PubMed ID: 18435430 [TBL] [Abstract][Full Text] [Related]
47. Orphan economics: the downside of supplyside pharmacology. Samson K Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669 [No Abstract] [Full Text] [Related]
48. Understanding orphan drug regulations: an EU and U.S. comparative analysis. Grienenberger A J Biolaw Bus; 2004; 7(3):58-61. PubMed ID: 15460604 [TBL] [Abstract][Full Text] [Related]
49. Approaches to cooperation on the discovery of new therapies for rare disorders. Hauck FP Prog Clin Biol Res; 1985; 197():175-8. PubMed ID: 4070292 [No Abstract] [Full Text] [Related]
51. Genentech lose Protropin case. Ezzell C Nature; 1987 Oct 1-7; 329(6138):379. PubMed ID: 3657956 [No Abstract] [Full Text] [Related]
52. Seeing the duties to all. Zoloth L Hastings Cent Rep; 2001; 31(2):15-9. PubMed ID: 11478102 [No Abstract] [Full Text] [Related]
53. Antitrust law may be the new regulator of the nation's health industry in the 1980s. Rev Fed Am Hosp; 1981; 14(3):12-4, 16. PubMed ID: 10251318 [No Abstract] [Full Text] [Related]
54. Lucrative niches: how drugs for rare diseases became lifeline for companies. Anand G Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531 [No Abstract] [Full Text] [Related]
56. The European rare diseases therapeutic initiative. Fischer A; Borensztein P; Roussel C PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832 [TBL] [Abstract][Full Text] [Related]
57. FDA launches priority vouchers for neglected-disease drugs. Waltz E Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849 [No Abstract] [Full Text] [Related]
58. The costs and economics of modern vaccine development. Batson A Dev Biol (Basel); 2002; 110():15-24. PubMed ID: 12477302 [No Abstract] [Full Text] [Related]
59. When drugs are in short supply. Zurlinden J Nurs Spectr (Wash D C); 1999 Feb; 9(4):15-6. PubMed ID: 10542818 [No Abstract] [Full Text] [Related]